Form 4: Humana Director Boosts Stake with Deferred Stock Units

Humana Director Gordon Smith acquired additional restricted stock units through compensation deferrals and dividend reinvestment, increasing his beneficial ownership.

Summary

• Gordon Smith, a Director at Humana Inc. (HUM), reported changes in his beneficial ownership of company securities.
• He acquired 766 restricted stock units (RSUs) as an annual Director's fee, deferred until his resignation, payable 1-for-1 in common stock. The transaction date was January 2, 2026.
• An additional 122 RSUs were acquired from converting a Director's cash fee, deferred until resignation, at a price of $258.8675 per unit. The transaction date was December 31, 2025.
• He also acquired 10 RSUs through dividend reinvestment on vested and deferred stock units, deferred until resignation, at a price of $258.8675 per unit. The transaction date was December 31, 2025.
• Following these transactions, Gordon Smith directly beneficially owns 765 shares of Humana Common stock.
• His total beneficial ownership of derivative securities (Restricted Stock Units) is 1,549 units after the January 2, 2026 transaction.

Sentiment

Score: 7

Explanation: The filing indicates a director increasing their stake in the company through compensation, which is generally a positive signal of confidence and long-term alignment, though not a discretionary open-market purchase.

Positives

• A Director increasing their beneficial ownership, even through compensation, can signal confidence in the company's future performance.
• The deferral of stock units until resignation aligns the Director's long-term interests with those of shareholders.

Future Outlook

The acquired restricted stock units are deferred and will be payable in Humana Inc. common stock on a 1-for-1 basis upon the reporting person's resignation of services as a director.

Industry Context

The acquisition of restricted stock units as part of director compensation, with deferral until resignation, is a common practice in publicly traded companies. This structure is designed to align the interests of directors with long-term shareholder value.

Comparison to Industry Standards

• Humana's director compensation structure, involving restricted stock units deferred until resignation, is consistent with best practices observed in the healthcare and broader corporate sectors. Companies like UnitedHealth Group (UNH) and CVS Health (CVS) also utilize equity-based compensation for their directors to foster long-term alignment.

Corporate Governance

Related Party Transactions

• The transactions represent compensation paid to a director, which is a standard related-party transaction disclosed in accordance with SEC regulations.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with long-term shareholder value due to deferred equity compensation.
• Management: Reinforces the company's compensation philosophy for its board members.

Next Steps

• The acquired restricted stock units will convert to Humana Inc. common stock upon Gordon Smith's resignation as a director.

Key Dates

Recommendation

This Form 4 filing details routine compensation-related acquisitions of restricted stock units by a director. While it indicates alignment of interests, it does not represent a discretionary open-market purchase or provide new material information that would significantly alter the investment thesis for Humana Inc. Therefore, it does not warrant a change from a 'hold' position based solely on this filing.

Keywords

Humana, HUM, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, RSU, Beneficial Ownership